Shionogi & Co. Ltd.'s novel antibiotic cefiderocol (S-649266) is on track for a US NDA submission for complicated urinary tract infections (cUTI) sometime this year following promising top-line results in a pivotal registrational study.
The siderophore cephalosporin met its primary endpoint of non-inferiority to imipenem/cilastatin in the patients with serious Gram-negative bacterial cUTI, and...






